2025 Guide to Digital Therapeutics Reimbursement (CPT®, HCPCS, AI, CMS/AMA)
The document includes verified CPT® and HCPCS codes, AI Category III routes, real-world case studies, state and federal policy signals, and expectations for developments through 2027.
By Odelle Technology · 3 November 2025 · ~12–14 min read
This expanded 2025 guide to digital therapeutics reimbursement explains verified CPT® and HCPCS codes, the CMS & AMA policy drivers behind them, real-world case studies, and what federal and state agencies are doing to pay for digital health.
Contents: Why new codes were created. · Agencies & departments · Verified CPT/HCPCS codes · Clinical workflows & business models · State-level initiatives · Case studies · Remaining gaps · Outlook 2025–2027 · Glossary · FAQ · References
Scope: Verified CPT®, HCPCS & AI Category III coding routes for digital therapeutic reimbursement in 2025.
Table of Contents
- Why new digital therapeutics codes were needed
- Key U.S. departments & agencies
- Verified CPT® & HCPCS codes (2025)
- How the codes work in practice
- State-level momentum (2024–2025)
- Case studies & human stories.
- EU/UK bridge: DiGA·PECAN·NICE EVA/DTAC
- Remaining gaps & policy challenges.
- Outlook 2025–2027
- Glossary
- FAQ
- References & official guidance.
The 2025 Shift to Digital Therapeutics Reimbursement: Why New CPT® and HCPCS Codes Matter. Why new digital therapeutics reimbursement codes were needed
The 2025 Shift to Digital Therapeutics Reimbursement: Why CMS and AMA Created New CPT® and HCPCS Codes
Between 2020 and 2025, the Centers for Medicare & Medicaid Services (CMS) and the American Medical Association (AMA) overhauled the CPT® and HCPCS coding systems to close a major reimbursement gap in U.S. healthcare.
Their goal was simple — to allow billing for evidence-based digital therapeutics (DTx), remote monitoring (RPM/RTM), and AI-enabled decision-support software just like traditional clinical services.
For the first time, physicians, behavioural healthcare specialists, and rehabilitation teams could be reimbursed for digital-first interventions rather than only face-to-face encounters.
Before these reforms, the U.S. payment system was built almost entirely around in-person visits and procedural billing.
Although FDA-cleared software-as-a-medical-device (SaMD) tools and connected sensors were advancing rapidly, there were no CPT or HCPCS structures to recognise digital therapy delivery, app-based adherence tracking, or algorithmic analysis.
CMS initially covered only a few remote physiological monitoring (RPM) codes, leaving innovative digital programs outside the reimbursement landscape.
The 2020–2025 reforms changed that.
By embedding digital care coordination, data interpretation, and AI-supported triage directly into CPT and HCPCS descriptors, CMS and AMA formally acknowledged the clinical and economic value of software-based interventions.
This policy alignment marked the transition from volume-based to value-based care, rewarding outcomes instead of activity.
Scientific and economic evidence drove these changes.
Studies funded by the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ) demonstrated that digital therapeutics and connected monitoring programs reduce hospital readmissions, improve medication adherence, and lower the total cost of care by 10–15 percent in chronicdisease management.
By reimbursing clinicians for reviewing digital data and managing patients remotely, CMS effectively created a bridge between clinical outcomes and reimbursement policy, ensuring that real-world evidence (RWE) now drives payment.
Key U.S. Departments and Agencies Shaping Digital Therapeutics Reimbursement Policy (2025)
The U.S. reimbursement ecosystem for digital therapeutics (DTx), AI-driven diagnostics, and connected-care platforms depends on coordinated policy action across multiple federal agencies.
Each organisation plays a crucial role in defining and implementing CPT® and HCPCS codes, Medicare and Medicaid coverage, and real-world-evidence (RWE) frameworks.
CMMI — Center for Medicare & Medicaid Innovation
The Centre for Medicare & Medicaid Innovation (CMMI) is responsible for designing and piloting value-based care and remote-monitoring reimbursement models.
CMMI demonstration projects often become national payment policies, influencing HCPCS code adoption for RPM, RTM, and AI-enabled interventions.
(Entity keywords: CMS Innovation Center, value-based payment, digital health reimbursement)
HHS — U.S. Department of Health and Human Services
Oversees the federal Digital Health Strategy and administers telehealth and interoperability funding streams.
HHS makes sure that CMS payment systems include AI and digital treatments within the current CPT and HCPCS categories.
ONC—Office of the National Coordinator for Health IT.
Enforces FHIR (Fast Healthcare Interoperability Resources) and API standards so data from FDA-cleared digital therapeutics flow into EHRs for billing, outcome tracking, and RWE generation.
ONC certification is now a prerequisite for many DTx EHR integrations and Medicare billing compliance.
FDA Digital Health Center of Excellence
The FDA Digital Health Centre of Excellence regulates Software as a Medical Device (SaMD) and reviews AI/ML algorithms that support diagnosis or therapy optimisation.
FDA classification directly affects coverage and payment policy, establishing the scientific credibility needed for CPT and HCPCS valuation.
MedPAC & ASPE — Policy Advisors to Congress
The Medicare Payment Advisory Commission (MedPAC) and HHS Office of the Assistant Secretary for Planning and Evaluation (ASPE) analyse economic and policy impacts of AI and digital-health services.
Their recommendations shape pricing methodologies and guide Congressional review of CPT and HCPCS valuation models.
NIH & AHRQ — Evidence and Health-Economics Agencies
Fund national real-world-evidence studies, cost-utility (CUA), and QALY-based models proving the clinical and economic value of digital therapeutics across chronic-disease and behavioural-health domains.
These data underpin both CMS coverage decisions and HTA alignment with international frameworks such as DiGA (DE), PECAN (FR), and NICE EVA (UK).
Congress Access to Prescription Digital Therapeutics Act (PDTx)
Pending legislation (H.R. 1458) will create a Medicare benefit category for prescription digital therapeutics, providing national parity with pharmaceuticals.
Once enacted, CMS will issue dedicated HCPCS codes and national coverage determinations (NCDs) for qualifying DTx products. Key U.S. Departments & Agencies Driving Reimbursement Policy
- Key U.S. Departments & Agencies Driving the Digital Therapeutics Reimbursement Policy
- A network of U.S. federal agencies and policy bodies is shaping how digital therapeutics (DTx), AI diagnostics, and connected health tools are paid for across Medicare, Medicaid, and private plans. Each plays a distinct role in aligning reimbursement, evidence, and regulation.
- CMMI—Center for Medicare & Medicaid Innovation: Designs and tests new payment models for remote monitoring, chronic care management, and value-based digital interventions. CMMI pilots often inform national coverage and HCPCS code adoption.
- HHS — Department of Health & Human Services: Manages the national Digital Health Strategy and telehealth funding, helping to include DTx and AI-based services in the larger CMS payment systems.
- ONC — Office of the National Coordinator for Health IT: Makes sure that FHIR interoperability standards are followed, allowing data from approved digital therapeutics to be added to electronic health records (EHRs) for billing, tracking results, and gathering real-world evidence (R
- The FDA’s Digital Health Centre of Excellence regulates software as a medical device (SaMD), reviews AI-enabled clinical algorithms, and defines evidence requirements for DTx market authorisation. Its classifications often underpin payer and coding decisions.
- MedPAC and ASPE analyse economic and policy issues for Congress, helping to set pricing rules for digital and AI services and making suggestions on how to value CPT® and HCPCS codes.
- NIH & AHRQ: Fund national real-world evidence (RWE), cost-utility, and QALY-based models to demonstrate the safety, effectiveness, and cost impacts of digital therapeutics across chronic diseases and behavioural health.
- Congress—Access to Prescription Digital Therapeutics Act (PDTx): This law aims to create a specific Medicare benefit for prescription digital therapeutics, ensuring that they can be reimbursed nationwide and treated the same as regular medications.
Congress has verified the 2025 CPT and HCPCS reimbursement codes for digital therapeutics, remote monitoring, telehealth, and AI-enabled clinical workflows.
Between 2020 and 2025, the American Medical Association (AMA) and the Centers for Medicare & Medicaid Services (CMS) added new codes to help pay for digital therapeutics (DTx), remote monitoring, and AI-based diagnostics.
These codes now form the regulatory backbone for billing software-as-a-medical-device (SaMD) and connected care models in the U.S.
CPT 99453–99458 Explained: Remote Physiologic Monitoring (RPM) and Reimbursable Vital-Sign Tracking Remote Physiologic Monitoring (RPM)
These CPT® codes cover continuous data capture and clinician oversight of physiologic parameters such as blood pressure, oxygen saturation, heart rate, and weight.
They recognise both the technical infrastructure (device setup, data transmission) and the professional time required for interpretation and patient management.
| Code | Description | Key Points |
|---|---|---|
| 99453 | Initial device setup and patient education | This is done once per episode of care and includes onboarding and instruction. |
| 99454 | Device supply and daily data transmission (≥16 days / 30 days) | The device must be FDA-cleared and capable of automatic upload, and the payment is made on a monthly basis. |
| 99457 | The treatment management service includes the first 20 minutes per month. | It covers clinical time spent analysing patient data and communicating results. |
| 99458 | Each additional 20 minutes | Add-on code for extended clinician engagement and intervention. |
Sources: HHS Telehealth RPM Guide · CMS MLN RPM Sheet 2025
Behavioural & Therapeutic Data CPT® 98975–98981 Explained: Remote Therapeutic Monitoring (RTM) for Digital Therapeutics and Behavioural Health (2025)
RTM codes extend RPM by enabling reimbursement for non-physiologic data, for example, therapy adherence, musculoskeletal recovery, or respiratory tracking.
Unlike RPM, RTM can be used by non-physician providers, such as physical therapists or behavioural health specialists.
| Code | Description | Therapeutic Application |
|---|---|---|
| 98975 | Initial setup and patient education | This code is utilised for the onboarding process in digital physiotherapy or pulmonary rehab applications. |
| 98976 | Respiratory system data (per 30 days) | Programs for asthma, COPD, and sleep apnoea utilise connected inhalers or devices. |
| 98977 | Musculoskeletal system data (per 30 days) | This data pertains to digital therapeutics for post-surgical recovery, rehabilitation, or chronic pain. |
| 98980 | First 20 minutes of management per month | The role involves interactive communication with the patient/carer and the review of therapeutic data. |
| 98981 | Each additional 20 minutes | Add-on for extended management time. |
Sources: AMA RTM Overview · CMS Change Request RTM (2025)
Online Digital Evaluation & Management (E/M) + Virtual Check-ins
These codes reimburse clinicians for asynchronous digital interactions and secure messaging—an essential framework for digital therapeutics follow-up and AI-assisted triage.
| Code | Description | Typical Use |
|---|---|---|
| 99421 | Online digital E/M, 5–10 minutes | Quick patient check-ins through EHR or a secure portal. |
| 99422 | Online digital E/M, 11–20 minutes | Moderate case review or data feedback. |
| 99423 | Online digital E/M, 21+ minutes | Comprehensive remote consultation. |
| G2010 | Remote evaluation of recorded video or images | Store-and-forward telemedicine review. |
| G2012 | Virtual check-in, 5–10 minutes | Brief synchronous communication to assess treatment response. |
Integration tip: Many FDA-cleared DTx apps use these codes to reimburse clinician interaction time rather than the software itself.
Artificial Intelligence & Emerging Digital Diagnostics (Category III CPT®)
Category III CPT® codes track the adoption of AI-driven diagnostics and algorithmic analysis for long-term utilisation data.
These are temporary but vital for reimbursement pilots and real-world evidence (RWE) generation.
| Code | Description | Example Use Case |
|---|---|---|
| 0689T–0690T | AI ultrasound tissue characterisation. | The process involves the identification of patterns related to oncology or liver fibrosis. |
| 0741T | AI physiologic/radiology decision support. | The support includes automated ECG interpretation, arrhythmia detection, and image triage. |
| 0787T | AI cardiac function analysis | This code is used for the computation of echocardiographic strain or ejection fraction. |
Policy context: Category III codes do not have assigned national fees but can be reimbursed under Medicare Administrative Contractor (MAC) or value-based payment pilots. Data from these codes inform the transition to Category I status once clinical and economic value is validated.
Reference: AMA Category III CPT® Database.
How CPT®, HCPCS, RPM/RTM, and AI Codes Operate in Real-World Clinical and Reimbursement Workflows (2025)
The 2025 CPT® and HCPCS code families translate digital health innovation into reimbursable clinical activity. They allow hospitals, primary-care teams, and telehealth providers to record, transmit, and bill for remote physiologic or therapeutic monitoring, AI-assisted diagnostics, and digital-therapeutic management. Proper use of these codes underpins both evidence generation and value-based care contracting.
- Team time reimbursed: Remote Physiologic (RPM) and Remote Therapeutic Monitoring (RTM) codes compensate for the combined work of clinical staff, nurses, and supervising clinicians—recognising up to 40 minutes per month of structured review and patient communication.
- Data flows via FHIR: The Office of the National Coordinator for Health IT (ONC) mandates FHIR-based interoperability, ensuring that data from FDA-cleared Digital Therapeutics (DTx) and connected sensors populate electronic health records (EHRs) in a structured format suitable for clinical review and claims submission.
- Layered payment architecture: Providers can combine fee-for-service billing for RPM/RTM codes with value-based incentives tied to outcomes such as improved HbA1c, blood-pressure control, or reduced readmissions—bridging short-term reimbursement with long-term cost savings.
- Payer alignment and scalability: Major commercial insurers—including UnitedHealthcare, Cigna, and Aetna—have adopted CMS digital-care policies, mirroring RPM/RTM coverage in employer and Medicare Advantage plans. This alignment accelerates nationwide interoperability and payer acceptance of AI-enabled monitoring.
- Evidence and policy pipeline: The National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ) fund multi-centre real-world evidence (RWE) and cost-effectiveness analyses demonstrating that digital therapeutic interventions can reduce hospital utilisation and total cost of care by 10–15 percent.
Takeaway: These reimbursement codes formalise the operational link between FDA-cleared digital health technologies, clinical workflow integration, and payer recognition. They are the foundation of a scalable, AI-ready reimbursement ecosystem in the United States, and they are a reference model for Europe’s DiGA, PECAN, and NICE EVA programs.
State-Level Momentum (2024–2025)
California (CA DHCS & Medi-Cal)
Medi-Cal integrated RPM/RTM codes into managed-care contracts in 2024. Start-ups (e.g., digital asthma/diabetes programmes) bill these codes to support home-based care.
Texas (TX Medicaid & SB 670)
Senate Bill 670 requires Medicaid plans to cover telehealth and remote monitoring on par with in-person care. Clinical reviews reimburse RPM/RTM codes 99453–99458 and 98975–98981.
New York (Medicaid Telehealth Policy 2025)
New York expanded telehealth reimbursement to include behavioural health (DTx) and AI-supported screenings via OMH pilot grants and DOH rulemaking.
Case Studies & Human Stories
Three landmark examples illustrate how digital therapeutics (DTx) and AI-based diagnostics have moved from regulatory clearance to real-world coverage in the United States—and how their evidence models are now informing European programmes such as DiGA (Germany), PECAN (France), and NICE EVA (United Kingdom).
NightWare — AI Sleep Intervention for PTSD (VA & DoD)
What it is: NightWare is an FDA-cleared prescription digital therapeutic that uses data from the Apple Watch and iPhone to detect physiological signals—heart rate variability and motion—during sleep. When its algorithm identifies a pattern consistent with a nightmare, the app triggers gentle haptic feedback to interrupt the episode without fully awakening the user.
- Regulatory pathway: FDA De Novo DEN200033 (2020); Class II prescription-only device under 21 CFR 801.109. This approval created a new product classification for AI-based behavioural health interventions.
- Clinical evidence: Controlled and post-market studies across veteran and civilian populations demonstrated statistically significant improvements in Pittsburgh Sleep Quality Index (PSQI) and Nightmare Frequency Questionnaire scores. Adherence rates exceeded 85%, and no serious adverse events were reported.
- Coverage and reimbursement: NightWare is supplied via the U.S. Department of Veterans Affairs’ (VA) and TRICARE procurement channels under federal benefit programs. Clinician oversight can be billed under standard behavioural-health management codes (e.g., 99484, 99492–99494).
- Economic and policy relevance: Demonstrates a federal multi-agency coverage route—achieving access outside conventional CMS claims. It highlights the role of outcome-based procurement when traditional CPT®/HCPCS codes do not yet exist.
- EU/UK Bridge: Provides a direct analogue for PECAN early coverage pilots in France and NICE EVA in the UK, where AI-enabled behaviouralhealth apps can be conditionally funded while real-world evidence (RWE) accrues.
Takeaway: NightWare shows that insurance companies can accept new treatments based on their results and policy agreements, even if there isn’t a specific CPT® code—providing a way for government systems in the U.S. and EU to adopt AI therapies.
EndeavorRx® — Prescription Digital Therapeutic for ADHD (Akili Interactive)
What it is: EndeavorRx® (Akili Interactive) is the world’s first FDA-cleared video-game therapeutic, designed to improve attention function in children aged 8–12 with Attention-Deficit/Hyperactivity Disorder (ADHD). It uses an adaptive algorithm—the Selective Stimulus Management Engine™—to train attention control and executive functioning through dynamic gameplay.
- Regulatory pathway: FDA De Novo DEN200026 (2020) – Product Code QFT, classified as a “Digital Therapy Device for ADHD” under 21 CFR 882.5803.
- Clinical evidence: The pivotal STARS-ADHD randomised controlled trial (n = 348, Lancet Digital Health, 2020) showed a significant improvement in the Test of Variables of Attention (TOVA) Attention Performance Index vs active control. Follow-up studies (n > 500) demonstrated sustained gains in ADHD-RS Inattention and CGI-I scores with no serious adverse events.
- Safety and tolerability: Only mild transient effects—short-lived frustration (6%) and headache (1%)—were observed.
- Billing and coding: 0704T–0706T (Prescription digital behavioural therapy, FDA-cleared) are the primary CPT® codes, complemented by 98978 for RTM adherence tracking when therapy engagement is monitored digitally.
- Coverage pattern: Select Medicaid and commercial insurers (e.g., Molina Medicaid, Ohio) reimburse under outcome-based contracts linked to validated improvement metrics. Some payers continue to classify it as investigational pending additional RWE.
- Economic and policy insight: EndeavorRx® demonstrates that payer confidence depends on measurable clinical endpoints and transparent data-sharing frameworks, aligning reimbursement with evidence-based medicine.
- EU/UK bridge: Its adaptive dos
Relevance to EU and UK Pathways
While the United States leads in establishing structured CPT® and HCPCS billing codes for digital therapeutics (DTx) and AI-enabled monitoring, Europe is rapidly building parallel reimbursement frameworks. Across Germany, France, and the United Kingdom, new health technology assessments (HTAs) and funding mechanisms now support software-based medical interventions that generate real-world evidence (RWE) and deliver measurable clinical or organisational benefits.
Germany’s DiGA and DiPA Frameworks
The DiGA (Digitale Gesundheitsanwendungen) and DiPA (Digitale Pflegeanwendungen) programs—administered by the Federal Institute for Drugs and Medical Devices (BfArM)—allow prescribable and reimbursed digital health apps that demonstrate either a medical benefit or a positive healthcare process impact. Approved apps are listed in the official DiGA directory, reimbursed under statutory insurance, and must comply with GDPR, cybersecurity standards, and structured RWE plans.
AI-driven cardiology platforms—such as those using CPT® 0741T-equivalent algorithms—can qualify under DiGA if they demonstrate clinician efficiency gains (e.g., reduced ECG review time) and validated diagnostic accuracy. Integration with the TI (Telematikinfrastruktur) is a key requirement for interoperability.
France’s PECAN Early Coverage Framework
France’s PECAN (Prise en Charge Anticipée Numérique) program, introduced by the Haute Autorité de Santé (HAS) in 2023, provides one-year early reimbursement for mature digital health solutions while real-world data is collected. This “early funding bridge” helps support digital treatments, connected devices, and AI-based diagnostics that already meet safety, compatibility, and clinical standards.
PECAN allows manufacturers to generate cost-effectiveness and utilisation data within the French system before pursuing permanent LPPR or CCAM listing. AI cardiology and behavioural-health solutions (e.g., NightWare or EndeavorRx® analogues) could enter PECAN through partnerships with ARS, CNAM, and regional GHTs, where AMR and chronic disease programmes align with national digital health strategy.
United Kingdom — NICE EVA and DTAC
In the UK, the National Institute for Health and Care Excellence (NICE) supports early market access for digital therapeutics through the Evidence Standards Framework (ESF) and the Early Value Assessment (EVA) pathway. These frameworks evaluate technologies that show promising patient outcomes, cost savings, or workflow efficiency but lack long-term evidence. Successful products can be rapidly adopted into Integrated Care Systems (ICSs) under conditional funding agreements.
Compliance with the Digital Technology Assessment Criteria (DTAC)—covering information governance, cybersecurity, clinical safety, and interoperability—is mandatory for NHS procurement. This reflects U.S. rules for FHIR data sharing and protections similar to HIPAA, making NICE EVA the UK’s entry point for getting paid for and using digital therapies.
EU-Wide Regulation The EU AI Act
The upcoming EU Artificial Intelligence Act will set rules for AI-based medical devices, classifying them as “high-risk” and requiring clear human oversight, transparent data, efforts to reduce bias, and ongoing. Developers should plan for compliance early by making sure that their systems for generating evidence and managing quality are in line with both MDR and HTA Regulation 2021/2282. This ensures that AI-driven digital therapeutics meet future safety and reimbursement expectations across all EU markets.
Takeaway: Europe’s regulatory landscape is converging on the same principles that underpin the U.S. CPT®/HCPCS model—real-world evidence, measurable benefit, patient safety, and interoperability. For innovators, these frameworks create an unprecedented opportunity to align global reimbursement strategies and scale access across both U.S. and EU health systems.
The remaining gaps and policy challenges
Despite rapid progress in coding and regulatory clarity, several system-level barriers still constrain the full reimbursement of digital therapeutics (DTx) and AI-driven diagnostics. The most pressing challenges span legislation, payment methodology, administrative complexity, and evidence expectations across both U.S. and European markets.
- Legislative lag (United States): DTx technologies still lack a formal Medicare benefit category. The pending Access to Prescription Digital Therapeutics Act (H.R.1458)—often referred to as the PDTx legislation—would create a defined reimbursement class similar to pharmaceuticals. Until enacted, most digital therapeutics rely on existing Remote Physiologic Monitoring (RPM), Remote Therapeutic Monitoring (RTM), or CMMI pilot models for coverage. This legislative gap limits nationwide adoption and complicates payer parity across Medicare, Medicaid, and commercial plans.
- AI payment uncertainty: Category III CPT® codes—such as 0741T for automated physiologic analysis—enable tracking of AI-based clinical decision support but often lack national fee schedule rates. Coverage is specific to each Medicare Administrative Contractor (MAC) or payer, leading to geographic inconsistency. To transition to Category I status, manufacturers must demonstrate sustained utilisation, clinical validity, and real-world evidence (RWE) of patient benefits or workflow efficiency.
- Administrative burden: Current RPM billing rules require at least 16 days of transmitted data per 30-day period and restrict claim submission to a single supervising practitioner. Clinicians must document minute-level time (e.g., 20-minute increments under 99457/99458), which adds friction to scaling digital-care models. Simplified or automated reporting—through FHIR-integrated dashboards and AI-enabled data validation—could make it easier to follow the rules and lower the cost of delivery.
- Evidence expectations and payer confidence: Both CMS and commercial payers now require robust RWE, cost-utility analysis, and demonstration of health-economic value before expanding coverage. In Europe, parallel frameworks—such as NICE’s Evidence Standards Framework (ESF) in the UK, DiGA/DiPA in Germany, and PECAN in France—expected validated clinical outcomes, interoperability (FHIR/DTAC), and proof of organisational or resource efficiency. The absence of consistent global evidence standards remains a bottleneck for cross-market reimbursement.
Key insight: The next phase of digital-health reimbursement depends on policy synchronisation between CMS and international HTA bodies. Legislators and payers increasingly demand quantitative RWE, transparent data-sharing, cybersecurity assurance, and AI governance—all of which will define which digital therapeutics reach routine clinical use by 2027.
Outlook 2025–2027: Policy and Reimbursement Forecast
The next three years will define how digital therapeutics (DTx), AI-enabled diagnostics, and remote-monitoring technologies move from pilot status to mainstream reimbursement. U.S. and European agencies are converging on shared priorities: measurable outcomes, cost-effectiveness, and robust real-world evidence (RWE). As utilisation increases and legislative frameworks mature, several key developments are expected to reshape global payment pathways.
- Expansion of RTM body-system codes: The American Medical Association (AMA) is expected to broaden Remote Therapeutic Monitoring (RTM) coverage beyond respiratory and musculoskeletal systems to include cardiovascular, metabolic, neurological, and behaviouralhealth domains. This expansion will allow more DTx and connected-care platforms to be reimbursed under existing CPT® structures.
- Transition from Category III to Category I for DTx codes: As utilisation and published evidence grow, high-performing digital therapeutics—especially those delivering measurable clinical benefits or cost reductions—are likely to achieve Category I CPT® status. This conversion will establish permanent reimbursement rates and national coverage consistency.
- Federal legislation for prescription digital therapeutics (PDTx): The Access to Prescription Digital Therapeutics Act (H.R. 1458) would formally recognise digital therapeutics as a Medicare benefit class and define HCPCS coding pathways upon passage. These changes would mark the first statutory parity between software-based therapeutics and pharmaceuticals.
- In the next two years, most State Medicaid plans are likely to adopt the same payment policies as CMS, which will allow for consistent access to digital therapeutics and AI-based remote monitoring. Meanwhile, commercial insurers are expanding outcomes-linked and shared-savings contracts that tie payment directly to validated clinical and economic results.
- Scaling of NIH/AHRQ research funding: Both the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ) plan to expand investment in cost-utility and quality-adjusted life-year (QALY) analyses for digital care. These studies will build an evidence base for the inclusion of DTx in formal HTA and payer decision frameworks.
- Private-sector adoption of RWE-based value contracts: Major insurers and integrated delivery networks are formalising real-world evidence-based (RWE) value agreements for apps, wearables, and AI tools. Payment will increasingly depend on verified outcomes, such as reduced hospitalisation rates, improved adherence, or clinician time savings.
Strategic insight: Between 2025 and 2027, the digital-health ec
Glossary of Terms: Digital Therapeutics, AI, and U.S. Reimbursement Systems (2025 Edition)
Digital Therapeutics (DTx)
Definition: Evidence-based software interventions that deliver clinical treatments directly to patients, either independently or alongside pharmacologic or behavioural therapies.
Scientific Context: DTx must demonstrate clinical efficacy and safety in controlled trials or real-world evidence (RWE) studies, often focusing on chronic disease, mental health, or rehabilitation.
Reimbursement Relevance: Formally recognised by the FDA as Software as a Medical Device (SaMD); reimbursable through CPT® and HCPCS codes (e.g., 0704T–0706T, 98975–98981).
References:- FDA Digital Health Center of Excellence (SaMD Framework)
- Access to Prescription Digital Therapeutics Act (H.R.1458, 2024)
Software as a Medical Device (SaMD)
Definition: Software intended to perform medical functions without being part of a hardware device.
Scientific Context: Defined by the International Medical Device Regulators Forum (IMDRF) and regulated by the FDA under 21 CFR §820 and §801.109.
Reimbursement Relevance: SaMD classification underpins payer coverage, CPT®/HCPCS coding, and post-market surveillance requirements.
References:- FDA Guidance: Software as a Medical Device (SaMD): Clinical Evaluation (2021)
- IMDRF SaMD N41 Final: 2017
Remote Physiologic Monitoring (RPM)
Definition: Continuous collection and interpretation of physiological data (e.g., blood pressure, glucose, oxygen saturation) transmitted from a patient’s device to a healthcare professional.
Scientific Context: Validated in numerous NIH-funded studies as effective for chronic disease management, reducing readmissions and improving outcomes.
Reimbursement Relevance: CPT® 99453–99458 reimburse setup, data transmission, and professional management.
References:- CMS MLN Booklet: Remote Physiologic Monitoring (2025)
- AHRQ Evidence Report No. 238: Telemonitoring for Chronic Conditions
Remote Therapeutic Monitoring (RTM)
Definition: Collection and management of non-physiologic patient data related to therapy adherence, physical function, or response to treatment.
Scientific context: Introduced by the AMA in 2022 to recognise therapeutic software that captures patient-reported or sensor-derived functional data (e.g., digital physiotherapy, respiratory monitoring).
Reimbursement Relevance: CPT® 98975–98981 can be billed by physical therapists, occupational therapists, or clinical psychologists.
References:- AMA CPT® Editorial Summary (2025)
- CMS Change Request 13177 (RTM Policy Update)
CPT® — Current Procedural Terminology
Definition: A standardised coding system maintained by the American Medical Association (AMA) that describes medical, surgical, and diagnostic services.
Scientific Context: CPT® enables consistent data reporting and reimbursement across public and private payers.
Reimbursement Relevance: This refers to the foundation for all professional billing under Medicare and commercial plans, which includes RPM, RTM, and AI Category III codes.
References:- AMA CPT® Professional Edition 2025
- CMS Physician Fee Schedule Final Rule (CY2025)
HCPCS—Healthcare Common Procedure Coding System.
Definition: The federal-level code system used by CMS to describe products, supplies, and services not included in CPT®.
Scientific Context: This includes Level II alphanumeric codes for telehealth services, durable medical equipment, and new digital technologies.
Reimbursement Relevance: Essentials for payments under Medicare and Medicaid for items and services outside physician billing, including software licenses and remote monitoring devices.
References:- CMS HCPCS Level II 2025 Annual Update
- HHS Coverage Database
Category III CPT® Codes
Definition: Temporary tracking codes for emerging medical technologies, digital health, and AI algorithms.
Scientific context: Used to collect utilisation and performance data to justify the transition to permanent Category I codes.
Reimbursement Relevance: Enable provisional payment for AI-based or software-driven diagnostics (e.g., 0741T for AI physiologic analysis).
References:- AMA Category III CPT® Code Listing (2025)
- CMS National Payment Policy Workgroup
AI-Enabled Clinical Decision Support (CDS-AI)
Definition: Algorithms that analyse clinical or imaging data to assist diagnosis, risk stratification, or treatment selection.
Scientific Context: Must meet FDA criteria for “locked” or “adaptive” machine learning models with human oversight.
Reimbursement Relevance: Covered via Category III CPT® codes (0689T–0741T) or under CMMI innovation pilots.
References:- FDA Action Plan for AI/ML-Based Software as a Medical Device (2021)
- MedPAC Report to Congress (2024): Paying for AI-enabled Services
CMMI — Center for Medicare & Medicaid Innovation
Definition: A federal agency within CMS testing new payment and service delivery models.
Scientific Context: Evaluates the cost-effectiveness of digital health and AI-based chronic disease interventions under value-based care frameworks.
Reimbursement Relevance: CMMI pilots often determine future HCPCS inclusion or national coverage.
References:- CMMI Model Portfolio 2025
- CMS Innovation Center Annual Report 2024
Access to Prescription Digital Therapeutics Act (PDTx Act)
Definition: U.S. Congressional bill (H.R.1458, 2024) proposing a new Medicare benefit category for FDA-cleared prescription digital therapeutics.
Scientific Context: Establishes parity between software-based and pharmacologic therapies.
Reimbursement Relevance: Will formalise HCPCS codes and national coverage for DTx under Medicare.
References:- Congress.gov Bill H.R.1458 (2024)
- Digital Therapeutics Alliance (DTA) Policy Brief 2025
Real-World Evidence (RWE)
Definition: Clinical evidence derived from real-world data (RWD) on the usage and outcomes of a medical product.
Scientific context: supported by the FDA’s 21st Century Cures Act and NIH/AHRQ programs for pragmatic data collection.
Reimbursement Relevance: The core requirement for CMS coverage expansion and Category III→I conversion underpins the DiGA, PECAN, and NICE EVA frameworks in the EU and UK.
References:- FDA RWE Framework (2023 Update)
- NIH Collaboratory Pragmatic Trials Initiative
FHIR — Fast Healthcare Interoperability Resources
Definition: An HL7 interoperability standard that structures how health data are exchanged between systems.
Scientific Context: Required by the ONC for digital health integration; makes sure that data from Digital Therapeutics and Software as a Medical Device can be safely and effectively shared
Reimbursement Relevance: Prerequisite for ONC certification and payer billing compliance.
References:- HL7 FHIR R4 Implementation Guide (ONC Certified 2025)
- Office of the National Coordinator for Health IT (ONC) API Rule
Value-Based Care (VBC)
Definition: A reimbursement model rewarding healthcare providers for outcomes rather than volume.
Scientific Context: Measures quality metrics such as hospital readmission reduction, improved control of chronic conditions, and patient-reported outcomes.
Reimbursement Relevance: RPM and RTM codes directly support value-based contracts under CMMI and commercial payers.
References:- CMS Innovation Center Strategy Refresh (2025)
- NEJM Catalyst: Measuring Value-Based Health Care (2024)
Quality-Adjusted Life Year (QALY)
Definition: A composite measure of health outcome combining life expectancy and quality of life on a 0–1 scale.
Scientific Context: Used in cost-utility analysis (CUA) to assess the economic value of health interventions.
Reimbursement Relevance: Required in payer submissions and HTA models by AHRQ, ICER, and CMS for evaluating DTx value.
References:- ICER Value Assessment Framework (2024)
- Gold et al., Cost-Effectiveness in Health and Medicine (2nd ed., OUP)
Budget Impact Analysis (BIA)
Definition: An Economic assessment estimating the financial consequences of adopting a new intervention within a specific payer’s budget context.
Scientific Context: Complements cost-effectiveness models by focusing on short- to mid-term affordability.
Reimbursement Relevance: Essential for CMS and state Medicaid evaluations of digital therapeutic adoption.
References:- ISPOR Good Practice Guidelines (2023 Update)
- CMS Budget Impact Review Protocols
Centers for Medicare & Medicaid Services (CMS)
Definition: U.S. federal agency administering national health coverage, including reimbursement policy for RPM, RTM, and DTx.
Scientific Context: Develops annual Physician Fee Schedules and HCPCS updates that govern digital health payment.
Reimbursement Relevance: Sets national precedent for payer parity; its rulings are mirrored by private insurers.
References:- CMS CY2025 Physician Fee Schedule Final Rule
- CMS Medicare Learning Network (MLN) RPM Guide
American Medical Association (AMA)
Definition: U.S. professional body managing CPT® codes and clinical practice standards.
Scientific Context: Oversees evidence validation, stakeholder review, and valuation of CPT®/Category III codes.
Reimbursement Relevance: Gatekeeper of digital health code creation and conversion to permanent reimbursement.
References:- AMA CPT® Editorial Panel Actions (2025 Q2)
- AMA Digital Medicine Payment Advisory Group
Office of the National Coordinator for Health IT (ONC)
Definition: Federal office responsible for nationwide health IT and interoperability.
Scientific Context: Sets API, FHIR, and cybersecurity standards for certified EHRs and digital tools.
Reimbursement Relevance: Compliance is mandatory for DTx reimbursement and EHR integration.
References:- ONC Health IT Certification Program (2025)
- 45 CFR Part 170 — Information Blocking Final Rule
National Institutes of Health (NIH) / Agency for Healthcare Research and Quality (AHRQ)
Definition: U.S. agencies funding clinical and economic research on digital health and therapeutics.
Scientific Context: NIH’s Digital Health Initiative and AHRQ’s RWE funding streams produce outcomes data used in CMS and payer decisions.
Reimbursement Relevance: Provide cost-utility and QALY-based evidence models supporting DTx reimbursement.
References:- NIH Digital Health Initiative (2024–2026)
- AHRQ Health Systems Research Priorities
DiGA / DiPA (Germany)
Definition: Fast-track reimbursement systems for digital health and care applications administered by BfArM.
Scientific Context: Require proof of medical benefit or healthcare process improvement.
Reimbursement Relevance: The European reference model is influencing CMS and AMA policy development.
References:- BfArM DiGA Directory (2025)
- German Digital Healthcare Act (DVG)
PECAN (France)
Definition: Prise en Charge Anticipée Numérique — early reimbursement framework by HAS for digital health solutions.
Scientific Context: Provides one-year conditional coverage while RWE is generated.
Reimbursement Relevance: European parallel to Category III CPT® or CMMI pilot models.
References:- HAS PECAN Guidance (2024)
- CNAM Innovation Funding Framework
NICE EVA & DTAC (United Kingdom)
Definition: Early Value Assessment (EVA) and Digital Technology Assessment Criteria (DTAC) frameworks governing NHS digital health adoption.
Scientific Context: Evaluate safety, clinical performance, evidence strength, and data governance.
Reimbursement Relevance: Determine early NHS funding and procurement eligibility.
References:- NICE EVA Programme Overview (2025)
- NHS England DTAC Policy (2024 Revision)
EU Artificial Intelligence Act (AI Act)
Definition: EU Regulation (expected enforcement 2025–2026) governing high-risk AI systems, including healthcare algorithms.
Scientific Context: Requires transparency, bias mitigation, and human oversight.
Reimbursement Relevance: Compliance prerequisite for EU HTA and reimbursement under Regulation 2021/2282.
References:- Official Journal of the EU: COM/2021/206 Final
- European Commission AI Office (2025 Updates)
Health Economic Modelling (HEOR, CUA, CCA, BIA)
Definition: Quantitative frameworks translating clinical outcomes into cost, utility, and policy impact.
Scientific Context: Includes Cost-Utility Analysis (CUA), Cost-Consequence Analysis (CCA), and Budget Impact Analysis (BIA).
Reimbursement Relevance: Required by CMS, NICE, HAS, and IQWiG to justify pricing and inclusion in payer formularies.
References:- ISPOR–SMDM Modelling Best Practices Task Force (2023)
- CMS Value-Based Purchasing Roadmap (2024)
Interoperability & Cybersecurity Compliance
Definition: Ability of health IT systems to exchange and protect patient data according to standards (FHIR, HIPAA, NIST SP 800-53).
Scientific Context: Key determinant of payer acceptance and ONC certification.
Reimbursement Relevance: DTx and AI systems must meet interoperability and privacy benchmarks to qualify for coverage.
References:HHS Office for Civil Rights (OCR) HIPAA Security Rule
Digital Therapeutics (DTx) – Evidence-based software delivering a clinically validated intervention.
RPM – CPT 99453–99458 for vital-sign data review and monthly care management.
RTM – CPT 98975–98981 for therapy adherence and response tracking.
CPT® / HCPCS – Code sets maintained by AMA (CPT) and CMS (HCPCS).
Category III CPT® – Temporary tracking codes for emerging/AI tech (e.g., 0741T).
SaMD – Software as a Medical Device, regulated by the FDA.
FHIR – Interoperability standard enabling structured data exchange with EHRs.
RWE – Real-world evidence from routine use supporting coverage and pricing.
QALY – Quality-Adjusted Life Year; core metric in cost-utility analysis.
Frequently Asked Questions
1. What’s the difference between RPM and RTM?
Remote Physiologic Monitoring (RPM) codes (99453–99458) reimburse clinicians for collecting and reviewing vital-sign data such as blood pressure, SpO₂, and heart rate.
Remote Therapeutic Monitoring (RTM) codes (98975–98981) apply to therapy adherence, musculoskeletal or respiratory data, and digital therapeutic engagement.
2. Are AI-enabled diagnostics reimbursed today?
Yes—mostly under Category III CPT® codes (e.g., 0741T for AI physiologic analysis).
Coverage varies by Medicare Administrative Contractor (MAC) and commercial payer.
Widespread payment follows transition to Category I once real-world evidence (RWE) confirms safety and clinical benefit.
3. Do digital-therapeutic (DTx) codes apply outside mental health?
Absolutely. Newer FDA-cleared DTx target diabetes, COPD, insomnia, cardiology, and neuro-rehabilitation, using CPT 98975–98981 or AI Category III codes.
4. How can companies secure coverage faster?
Run payer-aligned RWE pilots with clear clinical endpoints.
Ensure FHIR-based data integration, publish validated outcomes, and link to appropriate CPT/HCPCS codes before submission to CMS or private insurers.
5. Why did CMS and AMA create new CPT and HCPCS codes?
To reward outcome-based digital care. Between 2020 and 2025, they redesigned code families to reimburse AI-supported triage, RPM, and DTx management within Medicare and Medicaid.
6. What evidence does CMS require for DTx reimbursement?
Clinical validity, utility, and RWE demonstrating improved outcomes or cost reduction (typically 10–15 %). Economic models such as BIA and CUA strengthen coverage applications.
7. How do CPT and HCPCS codes differ?
CPT® codes describe clinical services (billed by professionals); HCPCS Level II codes cover devices, software, and supplies reimbursed by CMS.
8. What are Category III CPT codes used for?
Temporary tracking of emerging technologies—especially AI and digital diagnostics—until RWE supports promotion to Category I with national fees.
9. Does FDA approval guarantee reimbursement?
No. FDA clearance (De Novo or 510(k)) confirms safety and efficacy but does not establish payment. Reimbursement requires CMS/AMA coding and payer value assessment.
10. How does FHIR support digital health billing?
The Fast Healthcare Interoperability Resources (FHIR) standard enables structured data exchange from DTx apps to EHRs for claim submission and outcome tracking—mandatory for ONC-certified systems.
11. Which U.S. agencies influence digital reimbursement policy?
CMS, CMMI, HHS, ONC, FDA, MedPAC, AHRQ, and NIH each shape coding, payment models, and RWE requirements for digital therapeutics and AI tools.
12. How do private insurers adopt CMS digital care policies?
Commercial plans (UnitedHealthcare, Cigna, Aetna) mirror CMS RPM/RTM coverage and often add outcomes-based contracts linking payment to validated results.
13. What is the Access to Prescription Digital Therapeutics Act (PDTx)?
Pending federal legislation (H.R. 1458) that would create a dedicated Medicare benefit category for prescription digital therapeutics and formal HCPCS codes.
14. Can non-physicians bill RTM codes?
Yes. Physical therapists, occupational therapists, and clinical psychologists may bill RTM 98975–98981, unlike RPM codes limited to physician supervision.
15. How is AI governed under the EU and U.S. systems?
In the U.S., FDA’s Digital Health Center of Excellence regulates SaMD. In Europe, the AI Act (2025) and MDR 2017/745 govern AI as a high-risk medical device.
16. What is RWE, and why is it essential for reimbursement?
Real-World Evidence (RWE) uses data from routine care to validate safety, effectiveness, and economic impact. Payers increasingly require RWE to set coverage and pricing.
17. How do RPM and RTM codes align with value-based care?
Both reward continuous engagement and preventive management, reducing readmissions and enabling shared-savings contracts under CMMI innovation models.
18. What are common billing errors with RPM/RTM codes?
Missing 16-day data requirement (RPM), incorrect supervising provider designation, and double-counting time between 99457 and 98980 lead to claim denials.
19. How is the economic value of DTx measured?
Through Cost-Utility Analysis (CUA), Budget Impact Analysis (BIA), and Quality-Adjusted Life Year (QALY) metrics evaluating clinical outcomes per cost.
20. What does 2025–2027 mean for digital health reimbursement?
Expect expansion of RTM body-system codes, promotion of high-performing DTx to Category I CPT, and full Medicare recognition via the PDTx Act, anchored in RWE and value-based care.
What’s the difference between RPM and RTM?
RPM (99453–99458) covers physiologic data like BP or SpO₂. RTM (98975–98981) covers therapy adherence or response data.
Are AI diagnostics reimbursed today?
Mostly via Category III CPT® (e.g., 0741T). Payment is determined regionally by Medicare contractors and commercial payers; broader adoption follows Category I conversion supported by RWE.
Do DTx codes apply outside mental health?
Yes. While early FDA-cleared DTx focused on behavioural health, newer tools target diabetes, COPD, insomnia, cardiology and neuro-rehab.
How can companies secure coverage faster?
- Generate RWE through payer-aligned pilots; publish outcomes.
- Ensure FHIR data flows and clean CPT/HCPCS linkage.
- Build a country-specific value story (DiGA organisational benefit, PECAN outcomes, NICE EVA/ESF + DTAC).
References & Official Guidance
Centers for Medicare & Medicaid Services (CMS)
- Telehealth & Remote Patient Monitoring — MLN Booklet (April 2025). MLN901705. CMS
- Medicare Telehealth: List of Services (last updated Dec 11, 2024) — includes annual facility-fee table and covered codes. CMS
- The CY 2025 Medicare Physician Fee Schedule Final Rule Fact Sheet, dated November 1, 2024, outlines payment policies that affect digital care and remote patient monitoring (RPM) and remote therapeutic monitoring (RTM).
The U.S. Department of Health & Human Services (HHS) oversees telehealth services.
- The HHS Telehealth provider guide for billing Remote Patient Monitoring (RPM) is available at telehealth.hhs.gov and was published on January 17, 2025.
- Billing for Telehealth (July 29, 2025) — overview across Medicare/MA/Medicaid/private plans. telehealth.hhs.gov
- Introduction to Telehealth & RPM (Aug 28, 2024) — clinical and operational overview. telehealth.hhs.gov
American Medical Association (AMA) — CPT®
- Digital Medicine Clinical Scenarios: Coding Handbook (Mar 10, 2025) — practical CPT guidance for RPM/RTM and digital services. American Medical Association
- CPT Updates Covering Digital Health & AI (Sept 12, 2025) — overview article on new/updated CPT codes (context for Category III/AI trajectory). American Medical Association
ONC — Interoperability / FHIR (HealthIT.gov)
- Cures Act Final Rule — API/Interoperability Requirements (Oct 23, 2020) — foundation for FHIR-certified data exchange used in billing/RWE. healthit.gov
- HTI-2 Proposed Rule Task Force Recommendations (Sept 19, 2024) — advancing interoperability/transparency for electronic health information. healthit.gov
- Standards Version Advancement Process (SVAP) — Approved Standards — ONC process document referencing eligible standards (FHIR). healthit.gov
U.S. Food & Drug Administration (FDA) — Digital Health / SaMD
- Digital Health Centre of Excellence (updated Jan 6, 2025) — hub for digital health policy and programmes. U.S. Food and Drug Administration
- Software as a Medical Device (SaMD) — Overview & IMDRF alignment — FDA explainer. U.S. Food and Drug Administration
- Guidance with Digital Health Content (live index, updated frequently) — current FDA guidance applicable to digital health/AI/SaMD. U.S. Food and Drug Administration
MedPAC — Medicare Payment Policy for Software
- Chapter 4: Paying for Software Technologies in Medicare — June 2024 Report to Congress (full chapter PDF). medpac.gov+1
- Paying for Medical Software Technologies — MedPAC Presentation (Apr 10, 2025) — SaaS/PDT context and Medicare payment systems. medpac.gov
Congress — Access to Prescription Digital Therapeutics Act (PDTx)
- H.R. 1458 (118th Congress) — Bill Summary — Access to Prescription Digital Therapeutics Act. Congress.gov
- H.R. 1458—Full Bill Text—statutory language proposing Medicare coverage for PDTx. Congress.gov
- H.R. 1458 — Cosponsors — legislative support roll. Congress.gov
- Centers for Medicare & Medicaid Services (CMS) – MLN Telehealth & RPM (2025)
- HHS Telehealth – RPM billing
- American Medical Association (AMA) – RTM/RPM code family; Category III CPT®
- ONC – FHIR interoperability standards
- FDA Digital Health Center of Excellence – SaMD resources
- MedPAC (2024) – Paying for software technologies
- Access to Prescription Digital Therapeutics Act (PDTx)
Need help activating digital therapeutics reimbursement codes for 2025?
Odelle Technology helps innovators secure CPT®/HCPCS coverage, generate real-world evidence, and align with CMS, Medicaid, commercial payers, and EU/UK routes (DiGA, PECAN, NICE EVA/DTAC).
Bridging the Gap: Odelle Technology’s U.S.–EU Reimbursement Analysis Framework
Securing reimbursement for digital therapeutics (DTx) and AI-enabled diagnostics requires deep understanding of how evidence, coding, and policy differ across the United States and European Union. Odelle Technology conducts structured gap analyses that map U.S. frameworks—such as CPT®/HCPCS, CMS coverage decisions, and PDTx legislation—against their European counterparts, including DiGA/DiPA (Germany), PECAN (France), NICE EVA & DTAC (UK), and the forthcoming EU HTA Regulation 2025/2282.
Our methodology identifies where evidence, coding, or economic data must be strengthened to achieve reciprocal reimbursement. This enables clients to move efficiently between FDA-cleared and CE-marked markets, accelerating access and reducing duplication of trials.
Core Components of Odelle’s Transatlantic Gap Analysis
- Regulatory & Evidence Mapping: Aligns FDA De Novo or 510(k) pathways with EU MDR Annex IX and national HTA expectations (HAS, IQWiG, NICE). We identify missing endpoints—clinical, usability, or economic—needed for European or U.S. payer acceptance.
- Code Translation & Cross-System Equivalence: Converts CPT®/HCPCS procedure and service codes to relevant LPPR, CCAM, EBM, or DiGA tariff codes. This highlights where new codes, Article 51 pilots, or NUB/innovation applications are required.
- Economic & HTA Readiness: Evaluates existing Cost-Utility (CUA), Budget Impact (BIA), and Cost-Consequence (CCA) models for compatibility with CMS, HAS, IQWiG, or NICE thresholds (ICER/QALY benchmarks).
- Real-World Evidence (RWE) Integration: Assesses the transferability of clinical-use data under HIPAA vs GDPR regimes, ensuring interoperability through FHIR R4 and alignment with ONC and DTAC interoperability standards.
- Policy & Payer Landscape Review: Benchmarks emerging value-based contracts, innovation pilots, and public-private coverage models (e.g., CMMI Innovation Models, PECAN, DiGA Fast-Track), mapping opportunities for parallel submission or conditional access.
Deliverables and Strategic Outcomes
- Side-by-side matrix of CPT®/HCPCS vs EU reimbursement pathways.
- Identification of missing RWE, comparator data, or cost endpoints required for HTA acceptance.
- Actionable roadmap for market access synchronisation (U.S. ↔ EU ↔ UK).
- Recommendations for pilot studies, pricing submissions, and payer engagement.
Odelle Technology’s comparative gap analysis helps medtech and digital-health innovators create unified reimbursement strategies across continents—bridging CPT® to DiGA, HCPCS to PECAN, and FDA RWE to NICE EVA. By aligning evidence with payer priorities, Odelle ensures that digital therapeutics can achieve sustainable access in both the U.S. Medicare/Medicaid system and European national health schemes.